TICS: Transcranial Magnetic Stimulation for Intervening in Children With Tourette's Syndrome (CIHR) (TICS-CIHR)
Primary Purpose
Tic Disorders
Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
rTMS + CBIT
Sham rTMS + CBIT
Sponsored by
About this trial
This is an interventional treatment trial for Tic Disorders focused on measuring Children, Adolescent, CBIT, Transcranial magnetic stimulation, Comprehensive Behavioral Intervention for Tics, rTMS, TMS, MRI, Tourette's Syndrome
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of Tourette's syndrome
- IQ greater than 80
- English fluency (to enable assent and consent).
Exclusion Criteria:
- Diagnosis of mania or schizophrenia
- Impediments to TMS or MRI.
Sites / Locations
- Alberta Children's HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
rTMS + CBIT
Sham rTMS + CBIT
Arm Description
Repetitive transcranial magnetic stimulation (rTMS) and Comprehensive Behavioural Intervention for Tics (CBIT)
Sham repetitive transcranial magnetic stimulation (rTMS) and Comprehensive Behavioural Intervention for Tics (CBIT)
Outcomes
Primary Outcome Measures
Yale Global Tic Severity Scale Total Tic score (YGTSS)
30% reduction in Yale Global Tic Severity Scale Total Tic score (YGTSS) (~9 point reduction).
A higher score on all scales suggests a more severe tics.
The YGTSS provides two tic severity scores:
Total Motor (0 to 25)
Total Phonic (0 to 25)
These are summed to form the Total Tic Severity Score (0 to 50). This is the measure for the primary outcome variable.
There is also the separate Impairment Dimension Score (0 to 50).
The total score is hence 0 to 100 (sum of Total Tic Severity Score and Impairment Dimension Score).
Secondary Outcome Measures
Supplementary Motor Area (SMA) GABA concentration as measured by LCModel (Institutional Units)
10% increase in GABA concentration in the Supplementary Motor Area (SMA) as measured by LCModel (Institutional Units)
Functional connectivity of the Supplementary Motor Area (SMA) and the dominant Primary Motor Cortex (M1)
Functional connectivity, as measured using SPM12, of the Supplementary Motor Area (SMA) and the dominant Primary Motor Cortex (M1).
Full Information
NCT ID
NCT03844919
First Posted
February 11, 2019
Last Updated
November 2, 2021
Sponsor
University of Calgary
Collaborators
Canadian Institutes of Health Research (CIHR)
1. Study Identification
Unique Protocol Identification Number
NCT03844919
Brief Title
TICS: Transcranial Magnetic Stimulation for Intervening in Children With Tourette's Syndrome (CIHR)
Acronym
TICS-CIHR
Official Title
TICS: Transcranial Magnetic Stimulation for Intervening in Children With Tourette's Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
November 2021
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2019 (Actual)
Primary Completion Date
May 1, 2022 (Anticipated)
Study Completion Date
November 1, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Calgary
Collaborators
Canadian Institutes of Health Research (CIHR)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Tourette's Syndrome (TS) is characterized by repetitive movements and vocalizations called tics. Due to the suffering caused by TS, children and adolescents often require treatment for their tics. The investigators' research focuses on developing novel repetitive transcranial magnetic stimulation (rTMS) interventions for child and adolescent neuropsychiatric disorders. In this project, the investigators will determine the effect of pairing 3 weeks of rTMS and HRT on tic severity and plasticity as indexed by supplementary motor area (SMA) y-aminobutyric acid (GABA) concentration and functional connectivity of the SMA to the primary motor cortex (M1) in children and adolescents with TS.
Children (N = 50, 6-18 years) with TS will be randomized to either a (1) rTMS+HRT arm, or (2) sham rTMS+HRT. Outcome measures will examine tic severity (primary), brain chemistry and function (secondary) at baseline and then at week 7. The investigators' proposed aims are:
(Aim 1) To determine the effect of paired rTMS and HRT on tic severity as measured by the Yale Global Tic Severity Scale (YGTSS) by comparing it to sham rTMS + HRT.
1-1: The investigators hypothesize that tic severity will decrease from baseline to post-treatment.
1-2: The investigators also hypothesize that the reduction in tic severity will be greater in the paired treatment group (rTMS+HRT > Sham rTMS+HRT).
(Aim 2) To determine the effect of paired rTMS and HRT on brain plasticity compared to sham rTMS + HRT.
2-1: The investigators hypothesize that patients treated with the paired rTMS and HRT will have a greater increase in GABA concentration comparted to sham and HRT.
2-2: The investigators also hypothesize that functional connectivity between the SMA and M1 will be greater with paired treatment (rTMS+HRT > Sham rTMS+HRT).
Detailed Description
Tourette's Syndrome (TS) is characterized by repetitive movements and vocalizations called tics. Due to the suffering caused by TS, children and adolescents often require treatment for their tics. Tic severity predicts poor outcomes across physical, psychological, and cognitive domains in youth. Current treatments for TS remain limited in scope and efficacy. Atypical antipsychotics are often used and for many patients have an unacceptable side effect burden. Behavioral treatments, like habit reversal therapy (HRT), show promise and are safe, but are predicated on a certain level of brain maturation to execute.
The investigators' research focuses on developing novel repetitive transcranial magnetic stimulation (rTMS) interventions for child and adolescent neuropsychiatric disorders. Plasticity, precision, and pairing are key considerations in this process. In this project, the investigators will determine the effect of pairing 3 weeks of rTMS and HRT on tic severity and plasticity as indexed by supplementary motor area (SMA) y-aminobutyric acid (GABA) concentration and functional connectivity of the SMA to the primary motor cortex (M1) in children and adolescents with TS. The investigators will use functional magnetic resonance imaging (fMRI) and robot controlled rTMS to precisely target the SMA. The investigators believe this pairing will provide improved relief by inducing plasticity to retrain the brain to be better at suppressing tics at an earlier age than usually expected.
Children (N = 50, 6-18 years) with TS will be randomized to either a (1) rTMS+HRT arm, or (2) sham rTMS+HRT. Outcome measures will examine tic severity (primary), brain chemistry and function (secondary) at baseline and then at week 7. The investigators' proposed aims are:
(Aim 1) To determine the effect of paired rTMS and HRT on tic severity as measured by the Yale Global Tic Severity Scale (YGTSS) by comparing it to sham rTMS + HRT.
1-1: The investigators hypothesize that tic severity will decrease from baseline to post-treatment.
1-2: The investigators also hypothesize that the reduction in tic severity will be greater in the paired treatment group (rTMS+HRT > Sham rTMS+HRT).
(Aim 2) To determine the effect of paired rTMS and HRT on brain plasticity compared to sham rTMS + HRT.
2-1: The investigators hypothesize that patients treated with the paired rTMS and HRT will have a greater increase in GABA concentration comparted to sham and HRT.
2-2: The investigators also hypothesize that functional connectivity between the SMA and M1 will be greater with paired treatment (rTMS+HRT > Sham rTMS+HRT).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tic Disorders
Keywords
Children, Adolescent, CBIT, Transcranial magnetic stimulation, Comprehensive Behavioral Intervention for Tics, rTMS, TMS, MRI, Tourette's Syndrome
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Children (N = 50, 6-18 years) with TS will be randomized to either a (1) rTMS+CBIT arm, or a (2) sham rTMS+CBIT arm.
Masking
ParticipantOutcomes Assessor
Masking Description
Eligible subjects will be randomly assigned to receive one of the two treatment regimens in a 1:1 ratio. Dr. Nettel-Aguirre will generate the sequence with random sized blocks of 2,4 and 6 and use the REDCap randomization module for recruiters to access the allocation for the subjects. The algorithm will stratify each by sex and age group (6-10, 11-14, 15-18 years). Dr. Zewdie will set up the rTMS accordingly for active or sham delivery. Participants and their parents will be blind to group status regarding sham vs. active rTMS. Dr. Wilcox, and all raters responsible for clinical evaluation under Dr. Wilcox's supervision, will also be blinded to group status.
Allocation
Randomized
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
rTMS + CBIT
Arm Type
Experimental
Arm Description
Repetitive transcranial magnetic stimulation (rTMS) and Comprehensive Behavioural Intervention for Tics (CBIT)
Arm Title
Sham rTMS + CBIT
Arm Type
Active Comparator
Arm Description
Sham repetitive transcranial magnetic stimulation (rTMS) and Comprehensive Behavioural Intervention for Tics (CBIT)
Intervention Type
Device
Intervention Name(s)
rTMS + CBIT
Intervention Description
Repetitive Transcranial Magnetic Stimulation (rTMS) parameters are: intensity 100% resting motor threshold (RMT), frequency 1Hz, duration = 30 minutes (1800 stimulations; 900 per side), target - the supplementary motor area (SMA). Treatments occur on weekdays (T - F) for four weeks (20 total).
The Comprehensive Behavioral Intervention for Tics (CBIT) will be completed over eight sessions that will average 60 minutes in duration. First, participants will undergo awareness training. Participants will then be introduced to competing response training, which involves performing a voluntary behaviour designed to disrupt the execution of the tic. The eight sessions will occur on Mondays, once a week for six weeks and then on weeks 8 and 10.
Intervention Type
Behavioral
Intervention Name(s)
Sham rTMS + CBIT
Intervention Description
Sham rTMS (sham coil) will be paired with CBIT. Sham rTMS will be delivered over the same time-frame as above. CBIT will be identical to the above.
Primary Outcome Measure Information:
Title
Yale Global Tic Severity Scale Total Tic score (YGTSS)
Description
30% reduction in Yale Global Tic Severity Scale Total Tic score (YGTSS) (~9 point reduction).
A higher score on all scales suggests a more severe tics.
The YGTSS provides two tic severity scores:
Total Motor (0 to 25)
Total Phonic (0 to 25)
These are summed to form the Total Tic Severity Score (0 to 50). This is the measure for the primary outcome variable.
There is also the separate Impairment Dimension Score (0 to 50).
The total score is hence 0 to 100 (sum of Total Tic Severity Score and Impairment Dimension Score).
Time Frame
Baseline to week 7
Secondary Outcome Measure Information:
Title
Supplementary Motor Area (SMA) GABA concentration as measured by LCModel (Institutional Units)
Description
10% increase in GABA concentration in the Supplementary Motor Area (SMA) as measured by LCModel (Institutional Units)
Time Frame
Baseline to week 7
Title
Functional connectivity of the Supplementary Motor Area (SMA) and the dominant Primary Motor Cortex (M1)
Description
Functional connectivity, as measured using SPM12, of the Supplementary Motor Area (SMA) and the dominant Primary Motor Cortex (M1).
Time Frame
Baseline to week 7
Other Pre-specified Outcome Measures:
Title
Yale Global Tic Severity Scale Total Tic score (YGTSS) post CBIT
Description
30% reduction in YGTSS (~9 point reduction)
30% reduction in Yale Global Tic Severity Scale Total Tic score (YGTSS) (~9 point reduction).
A higher score on all scales suggests a more severe tics.
The YGTSS provides two tic severity scores:
Total Motor (0 to 25)
Total Phonic (0 to 25)
These are summed to form the Total Tic Severity Score (0 to 50). This is the measure for this outcome variable.
There is also the separate Impairment Dimension Score (0 to 50).
The total score is hence 0 to 100 (sum of Total Tic Severity Score and Impairment Dimension Score).
Time Frame
Baseline to week 11
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of Tourette's syndrome
IQ greater than 80
English fluency (to enable assent and consent).
Exclusion Criteria:
Diagnosis of mania or schizophrenia
Impediments to TMS or MRI.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Frank MacMaster, PhD
Phone
4039552784
Email
fmacmast@ucalgary.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Rose M Swansburg, MBT
Phone
4039552784
Email
rose.swansburg@ucalgary.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Frank P MacMaster, PhD
Organizational Affiliation
University of Calgary
Official's Role
Principal Investigator
Facility Information:
Facility Name
Alberta Children's Hospital
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T3B 6A8
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Frank P MacMaster, PhD
Phone
403-955-2784
Email
fmacmast@ucalgary.ca
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Only de-identified data would be shared.
IPD Sharing Time Frame
Study protocol, SAP, and ICF is open to be shared now. De-identified data will be shared after we submitted our main papers. This is estimated in 2025.
IPD Sharing Access Criteria
Email for permission from PI of project.
Citations:
PubMed Identifier
34952879
Citation
Kahl CK, Swansburg R, Kirton A, Pringsheim T, Wilcox G, Zewdie E, Harris A, Croarkin PE, Nettel-Aguirre A, Chenji S, MacMaster FP. Targeted Interventions in Tourette's using Advanced Neuroimaging and Stimulation (TITANS): study protocol for a double-blind, randomised controlled trial of transcranial magnetic stimulation (TMS) to the supplementary motor area in children with Tourette's syndrome. BMJ Open. 2021 Dec 24;11(12):e053156. doi: 10.1136/bmjopen-2021-053156.
Results Reference
derived
Learn more about this trial
TICS: Transcranial Magnetic Stimulation for Intervening in Children With Tourette's Syndrome (CIHR)
We'll reach out to this number within 24 hrs